🏢 Company Overview
-
Full Name: Novartis AG
-
Headquarters: Basel, Switzerland
-
CEO: Vas Narasimhan
-
Industry: Pharmaceuticals & Biotechnology
-
Employees: ~78,000
-
Website: www.novartis.com
Novartis is one of the world’s leading pharmaceutical companies, focused on innovative prescription medicines in cardiovascular, oncology, immunology, neuroscience, and rare diseases. The company sells products in over 118 countries and helps more than 250 million patients each year.
📊 Key Financials (2024 Results)
-
Revenue: $50.6 billion
-
Net Income: $8.6 billion
-
Free Cash Flow: $11.7 billion
-
ROCE (Return on Capital Employed): 23.2%
-
R&D Investment: ~$10 billion
-
Dividend Growth: Increased for the 27th consecutive year
(Source: novartis.com)
🧪 Research & Development Highlights
-
Top Products:
-
Entresto – for heart failure
-
Cosentyx – for autoimmune diseases
-
Pluvicto – for prostate cancer
-
Kymriah – CAR-T cell therapy for blood cancers
-
-
Pipeline in 2025:
-
Over 15 major late-stage development projects
-
Advancing in targeted therapies, gene and cell therapies, and radioligand therapies
-
🔄 Strategic Shifts and Investments
-
Generics Exit: In 2023, Novartis completed the spin-off of Sandoz, its generics division.
-
U.S. Expansion: Plans to invest $23 billion over five years in U.S. manufacturing infrastructure.
-
Digital Innovation: Heavy investment in AI, data science, and digital health tools to accelerate R&D and patient access.
📈 Stock Info (as of May 7, 2025)
-
Ticker Symbol: NOVN (SIX Swiss Exchange)
-
Share Price: ≈ CHF 90.35
-
Market Capitalization: ~$190 billion